Early drugability evaluation, a crucial part of drug discovery, mainly aims to assess the pharmacodynamics, pharmacokinetics, and safety of lead molecules in order to preliminarily determine their potential druggability in the early stages of drug discovery. Through early evaluation of the druggability of lead molecules, pharmaceutical companies can either select potential candidates more efficiently in terms of cost and time to continue their development, or terminate the study of candidates with poor druggability as early as possible, so as to enable more successful new drug development with reduced costs.

ZSHK has established research platforms for early in vivo and in vitro pharmacodynamics, pharmacokinetics, and safety evaluation, and is able to provide reliable data support for optimization and drugability of product candidates by using varying combinations of screening and evaluation methods, thereby accelerating the process of drug research and development and improving efficiency.

Excellent professional team: We have a professional team of experts experienced in pharmacology, pharmacokinetics and safety evaluation.

Advanced evaluation platform: We have established advanced platforms for early pharmacodynamics, pharmacokinetics and safety evaluation using the latest technologies and methods.

Comprehensive evaluation methods: We utilize multiple screening and evaluation methods to fully understand the drugability of candidates.

Efficient R&D process: We are able to quickly screen out potential candidates and accelerate drug development process through early evaluation.

Successful cases and partnerships: We have achieved successes in the field of druggability assessment and have established strong partnerships with multiple partners.